Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Research
Medicine—Review

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Yan-Hua Li a,b, Chen-Yu Hu a,b, Nan-Ping Wu a,b, Hang-Ping Yao a,b,* Lan-Juan Li a,b,*

a State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China
b Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 31003, China

Abstract
Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a de novo coronavirus—MERS-CoV—that is associated with high mortality. However, the mechanism by which MERS-CoV infects humans remains unclear. To date, there is no effective vaccine or antibody for human immunity and treatment, other than the safety and tolerability of the fully human polyclonal Immunoglobulin G (IgG) antibody (SAB-301) as a putative therapeutic agent specific for MERS. Although rapid diagnostic and public health measures are currently being implemented, new cases of MERS-CoV infection are still being reported. Therefore, various effective measures should be taken to prevent the serious impact of similar epidemics in the future. Further investigation of the epidemiology and pathogenesis of the virus, as well as the development of effective therapeutic and prophylactic anti-MERS-CoV infections, is necessary. For this purpose, detailed information on MERS-CoV proteins is needed. In this review, we describe the major structural and nonstructural proteins of MERS-CoV and summarize different potential strategies for limiting the outbreak of MERS-CoV. The combination of computational biology and virology can accelerate the advanced design and development of effective peptide therapeutics against MERS-CoV. In summary, this review provides important information about the progress of the elimination of MERS, from prevention to treatment.

Article Info
Article history:
Received 25 July 2018
Revised 24 October 2018
Accepted 12 November 2018
Available online 17 July 2019

Keywords:
MERS-CoV
Spike protein
Structural protein
Accessory protein
Nonstructural protein

1. Introduction
Coronavirus (CoV) is an enveloped, positive, single-stranded RNA virus that causes mild upper respiratory infections in humans. Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a de novo coronavirus—MERS-CoV. MERS-CoV was originally isolated from an Arab patient who died of respiratory failure and renal failure in 2012, and was classified as a member of the CoV family, which is lineage C of the genus Betacoronavirus. From April 2012 to 22 May 2019, the total global number of laboratory-confirmed MERS cases reported to the World Health Organization (WHO) was 2428, with 838 associated deaths, or a fatality of about 35% (40.43% in Saudi Arabia) [1]. Aside from MERS-CoV, only a few other CoVs are known to infect humans; these include human coronavirus (HCoV)-229E, HCoV-NL63, HKU1, and OC43, which usually result in relatively mild respiratory disease [2,3]. However, severe acute respiratory syndrome (SARS)-CoV and MERS-CoV are highly pathogenic and lead to high mortality, especially in the elderly and in immunocompromised patients [4,5]. MERS has broken out in 27 countries around the world, with major outbreaks occurring in Saudi Arabia, the United Arab Emirates, and Korea. The dromedary camel is the largest intermediate host for MERS-CoV, and bats are considered to be animal sources of MERS-CoV. However, the specific role of dromedaries in the transmission of the virus is not yet clear. To date, in addition to the safety and tolerability of the fully human polyclonal Immunoglobulin G (IgG) antibody (SAB-301), which is described as a putative therapeutic agent specific for MERS, no effective vaccines or antibodies have been reported for human immunization and therapy [6]. Therefore, different intervention methods are need to treat MERS patients, including control of transmission. In this review, we describe the structure and potential functions of the reported MERS-CoV proteins, and discuss how their respective intervention strategies prevent virus transmission.

https://doi.org/10.1016/j.eng.2018.11.035
2095-8099/© 2019 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
2. Structural proteins

Many CoVs, including MERS-CoV, have a very large RNA genome of about 30 kb with at least ten predicted open reading frames (ORFs) [3,7]. The ORFs for the structural proteins are arranged as 5′-ORF1a/b-S-E-M-N-poly(A)-3′, which is a similar arrangement to that of other CoVs in lineage C of the genus Betacoronavirus [8]. Research has targeted these genes and their encoded proteins for use as vaccines, or for diagnostic or therapeutic purposes (Table 1) [9,10].

Like other CoVs, MERS-CoV carries genes encoding accessory proteins (APs; 3, 4a, 4b, and 5), which antagonize host antiviral responses—typically type I interferon (IFN) responses—and contribute to virulence and pathogenesis. When expressed alone, CoV APs appear to interfere with the innate antiviral signaling pathway [11].

2.1. Spike protein

The spike (S) protein of MERS-CoV is a type I transmembrane glycoprotein that is expressed on the surface of the envelope of the virus and forms spikes from the virus body. The S protein comprises 1353 amino acids, is heavily glycosylated, and has a large extracellular domain and a short cytoplasmic terminal. S protein can be subdivided into S1 and S2, which have important effects in virus binding, fusion, and entry.

2.1.1. Binding

The S1 subunit has an N-terminal domain (NTD) and a receptor-binding domain (RBD), and comprises about 240 residues. MERS-RBD contains internal and external subdomains. The internal subdomains are relatively conserved among CoVs [12], whereas the structure of the external subdomains in CoVs varies greatly; the external subdomains mainly participate in receptor binding, resulting in the use of different receptors between CoVs. The RBD is responsible for the binding of dipeptidyl peptidase IV (DPP4, also known as human CD26). Interestingly, MERS-RBD can induce strong production of antibodies in vivo, which indicates that the S protein has a good immunogenicity for the induction of neutralizing antibodies (nAbs) [13–16]. The immunogenicity and protective potential of the NTD have been studied, and the recombinant N-terminal domain (rNTD) is a candidate vaccine against MERS [17].

2.1.2. Viral fusion

There are two regions in the S2 subunit that participate in viral fusion—namely, heptad repeat 1 and 2 (HR1 and HR2), which assemble into a typical six-helix bundle (also called the fusion core). Three HR2 chains in the HR1 side groove core emit three HR1 spirals, forming a central coiled spiral core that is a key membrane fusion structure [18,19]. Upon binding of S1 and DPP4, HR1 binds HR2 to form a temporary intermediate structure, causing the viral and cell membranes to move in close proximity to fuse the membranes.

2.1.3. Virus entry

The S protein plays a key role in CoV tropism and morbidity, with proteolysis between S1 and S2 [20]. There are many kinds of proteases (reviewed in Ref. [21]) in hosts that can digest the S protein of MERS-CoV. For example, furin can be used in two steps by MERS-CoV in the activation process of cleavage during infection. First, furin recognizes the R751/S752 position and cleaves the S protein during biosynthesis. Next, S2 is further digested to S2′ at position R887/S888, which is adjacent to the fusion peptide after viral entry [20].

Table 1
Structural proteins, genes, and their potential functions in MERS-CoV.

| Proteins                    | Coding genes | Functions and/or effect on the cellular response of the host |
|-----------------------------|--------------|-------------------------------------------------------------|
| Spike (S) protein           | ORF2         | Viral entry, receptor binding, membrane fusion             |
| Envelope (E) protein        | ORF6         | Virion assembly; putative ion channel activity and is involved in viral budding and release; potential B cell epitopes |
| Membrane (M) protein        | ORF7         | Virion assembly—the formation of the viral envelope and viral core by interacting with the N protein; IFN antagonist |
| Nucleocapsid (N) protein    | ORF8a        | Main component of the nucleocapsid structure—essential for viral replication and assembly, and post-translational modification Modulating the host's initial innate immune response |
| AP 3                        | ORF3         | Viral replication and pathogenesis                          |
| AP 4a                       | ORF4a        | Viral replication, IFN antagonism, protein kinase R (PKR) antagonism |
| AP 4b                       | ORF4b        | IFN antagonism, nuclear factor kappa B (NF-kB) inhibition |
| AP 5                        | ORF5         | IFN antagonist, modulation of NF-kB-mediated inflammation |
| Nsp1-coding region          | nsp1         | Specific recognition of viral RNA that is required for efficient viral replication; possibly interacts with cyclophilins and is thought to be a major virulence factor because it suppresses protein synthesis through the degradation of host mRNA |
| Papain-like protease (PLpro)| nsp3         | PLpro is responsible for the cleavage at positions 1–3 to develop three nonstructural proteins (nsp5); two selected sites (G720 and R911) were detected in the protease domain; viral replication; membrane proliferation; IFN antagonist; deubiquitination; putative dephosphorylation of Appr-1"-p, a side product of cellular tRNA splicing, to ADP-ribose |
| Transmembrane domain        | nsp4         | Viral replication; membrane proliferation                   |
| Main, chymotrypsin-like, or 3C-like protease (3CLpro) | nsp5 | Viral survival—proteolytic processing of the replicative polyprotein at specific sites and 3CLpro cleaves the remaining positions 4–16 key functional enzymes, such as replicase and helicase |
| Transmembrane domain        | nsp6         | Membrane proliferation; interaction with nsp3 and nsp4 |
| Primase                     | nsp8         | Primase activity                                           |
| Unknown                     | nsp9         | Nsp9 is an essential protein dimer with RNA/DNA binding activity in SARS-CoV |
| Unknown                     | nsp10        | Membrane proliferation—regulating 2′-O-MTase activity       |
| RNA-dependent RNA polymerase| nsp12        | Viral replication and transcription                         |
| Superfamily 1 helicase      | nsp13        | Viral replication; affects tropism and virulence            |
| 3′-to-5′ exonuclease         | nsp14        | Viral replication—exonuclease activity                     |
| N7-methyltransferase        | nsp15        | Viral replication—exonuclease activity                     |
| Endonucleoside-specific for U| nsp16        | Methyltransferase inhibition; viral replication; IFN antagonism |
2.2. Envelope protein

The envelope (E) protein is an inner membrane protein that is also a small structural protein of MERS-CoV; it is 82 amino acids in length and is predicted to contain at least one transmembrane helix [22]. The E protein of CoVs plays an important role in intracellular trafficking, host recognition, viral assembly, and virus budding [22]. However, the exact function of the CoV E protein during infection remains unclear.

2.2.1. Virion assembly

Researchers have used infectious bronchitis virus (IBV) infection to prove that the E protein is required for virion assembly, and that its role is disturbing the secretory pathway [23]. The MERS-CoV E protein has a single hydrophobic domain (HD) that targets the Golgi composite membrane and has cationic channel activity in vitro. The purified MERS-CoV E proteins form pentameric ion channels in the lipid bilayer. Lack of the E protein may lead to elimination of channel activity. Based on the proposed channel activity as a virulence factor, the MERS-CoV E protein is a potential antiviral therapeutic target [22].

2.2.2. B cell epitopes

Researchers have used software or programs such as LaserGene (DNASTAR, Inc., USA), PHYRE 2 (Structural Bioinformatics Group, Imperial College London, UK), and PyMOL (Schrödinger, LLC, USA) to identify a potential B epitope with high antigenicity at positions 58–82 of the E protein [24].

2.3. Membrane protein

The membrane (M) protein is important in viral assembly, the formation of the viral envelope, and the formation of the viral core by interacting with the nucleocapsid (N) protein [25,26]. Therefore, the development of fusion peptides and IFN antagonists may be an important treatment option.

2.4. Nucleocapsid protein

The N protein of MERS-CoV is a phosphorylated basic protein and is the second largest structural protein, containing 413 amino acid residues. The N protein binds to the RNA genome to form a nucleocapsid, which is important in virus replication and assembly [27].

2.4.1. Virion replication and assembly

The N-terminus of the N protein (residues 39–165) may be the RNA-binding region, and the C-terminus may be a self-binding oligomer-forming region [28]. A comparison of homology between MERS-CoV and other CoVs shows that although the N protein has low homology over the entire amino acid sequence, certain local amino acid sequences—especially the N-terminal amino acid sequence—are highly conserved. The SARS-CoV N protein can increase replication by overexpression [29]. The nucleocapsid structure not only requires the recognition of the characteristic sequences of the viral RNA, but also must recognize binding to other structural viral proteins. After the N protein forms a complex with the viral genomic RNA, the RNA is protected from destruction by nucleases in the host cell [30]. X-ray diffraction measurement at very high resolution (2.4 Å) was used to discover an intrinsically disordered region (IDR) and an NTD at the N-terminus of the N protein. This model shows that the NTDs in CoVs are relatively conserved [31].

2.4.2. Post-translational modification

The N proteins of SARS-CoV and MERS-CoV are ADP-ribosylated, which is a common post-translational modification; however, it is unclear how this regulates RNA virus infection. In a study that screened for ADP-ribosylating proteins after infection with CoV, researchers identified an ADP-ribosylated protein of about 55 kDa in vivo, which was subsequently verified as a CoV N protein. Therefore, CoV N proteins may modulate the post-translational modification of certain important proteins [30].

2.4.3. Modulation of the innate immune response

The N protein of CoV may inhibit type I IFN production by interfering with the interaction between the triple motif protein 25 (TRIM25) and retinoic acid-inducible gene I (RIG-I), and by binding to the E3 ubiquitin ligase of TRIM25. Thus, inhibiting the ubiquitination and activation of RIG-I mediated by TRIM25 ultimately leads to the inhibition of IFN production, suggesting that the N protein of a CoV regulates the host’s immune response against the virus [29].

The MERS-CoV N protein is thought to interact with mannose-associated serine protease 2 (MASP2) [32] and translation elongation factor 1 (EF-1A) [33] in the host. Once the mannose-binding lectin recognizes the mannan on the surface of the virus-infected cell, it recruits MASP2 and then activates its enzymatic activity, eventually causing a local or systemic inflammatory response. EF-1A acts as a translation elongation factor, and catalyzes the aminoacyl-tRNA to the A site in the ribosome. EF-1A can play a regulatory role in the assembly of the cytoskeleton, microfilaments, and cytokinesis rings. The interaction between the MERS-CoV N protein and EF-1A disrupts the formation of cytokinesis loops and inhibits lymphocyte proliferation, which may explain the reduction in the number of lymphocytes in patients with MERS.

3. Accessory proteins

MERS-CoV has a large number of genomes encoding a variety of APs (dORF: ORF3, ORF4a, ORF4b, ORF5). Even among closely related CoVs, their number and sequence are different, and lead to host shift and HCoV emergence [34].

3.1. Viral replication

The MERS-CoV AP ORF is important for the replication of the virus in vivo and in vitro, which allows these ORFs to be used as targets of vaccine production, and emphasizes that MERS-CoV APs are potential targets for monitoring and therapeutic treatment. In addition, parallel disruption of the AP ORF provides a rapid response platform for new mutations of SARS or MERS-CoV AP ORFs [35].

3.2. Dysregulating host responses

The APs of MERS-CoV may invoke a hostile response through different modes, including IFN antagonism and the protein kinase R (PKR) and nuclear factor kappa B (NF-κB) pathways.

3.2.1. IFN antagonism

The attenuated function of dORF3-5 mutants is mainly caused by host-response disorders, including disrupted cellular processes and strong inflammation. ORF4-5 proteins increase IFN pathway activation and are potent IFN antagonists. They can inhibit IFN production (e.g., IRF-3/7) and interferon stimulated response element (ISRE) signaling pathways. The MERS-CoV ORF4a protein most likely interferes with the anti-antiviral effects of IFNs [36].
IFN antagonism is a key element of viral pathogenesis. The IFN-inducible oligoadenylate synthase (OAS)-RNase L pathway is activated after the sensing of viral double-stranded RNA (dsRNA); thus, the virus and single-stranded RNA (ssRNA) of the host are cleaved, which hinders the replication and spread of the virus. ORF4b, which is mainly located in the nucleus (while all the other proteins are located in the cytoplasm), has phosphodiesterase (PDE) activity and activates RNase L. Treatment with NS4b interferes with the pathogenesis of MERS-CoV in in vivo models [37].

3.2.2. PKR antagonism
The p4a of MERS-CoV is essential for PKR antagonistic activity. To establish infection and spread, MERS-CoV must regulate a complex antiviral host-response network (type I IFN (IFN-α/β) responses). Phosphorylation of eIF2α by PKR leads to inhibition of the translation of cells and viruses, and the formation of stress granules (SGs), which provide platforms for antiviral signaling pathways [38].

3.2.3. NF-κB inhibition
MERS-CoV 4b needs to prevent a strong host-dependent reaction during infection. During viral infection, 4b acts to interfere with NF-κB-mediated innate immune responses by binding NF-κB to nuclear transcription factor-κB (κB) (KPNAl) and translocating it to the nucleus to play a competitive role [20]. ORF5 also has some effect on the regulation of NF-κB-mediated inflammation [35].

4. Nonstructural proteins
ORF1a and ORF1b at the 5′-terminus of the CoV genome encode polyprotein 1a and polyprotein 1b, which may cleaved into 16 nonstructural proteins (nsps). These proteins are essential for viral replication and transcription [39].

4.1. Proteolysis
MERS-CoV 3C-like protease (3CLpro) and papain-like protease (PLpro) are affected by the different genetic and evolutionary effects of protein sequence formation, codon usage patterns, and codon usage bias. The cleavage points of PLpro are positions 1–3, which produces three nsps, while 3CLpro cleavage occur at the remaining positions 4–16. Nsp3 (~200 kDa) is a multifunctional protein that contains up to 16 different domains and regions, and is associated with viral RNA, nucleocapsid proteins, and other viral proteins involved in polyprotein processing. The PLpro activity of nsp3 is the established target of new antiviral drugs [40]. PLpro is controlled by a wide range of components, and other effects. Antiviral drugs, such as PLpro inhibitors and 3CLpro inhibitors (Table 2), have been studied for their innate immunosuppression profiles [41,42]. Nsp5 is widely involved in virus-encoded polyproteins (ppla, pplab) and 16 nsps processing; therefore, nsp5 is essential and indispensable for virus survival. In addition, the lack of cell homologs of human nsp5 makes it an ideal target for antiviral drug design [43]. The adaptive evolution of nsp3 in MERS-CoV strains is ongoing. CoV nsp3 can be used as a primary screening target, and nsp3 sequencing should be considered for monitoring and site-specific investigations [44].

4.2. Viral replication
CoV RNA synthesis is associated with replication organelles (ROs) composed of a modified endoplasmic reticulum (ER) membrane. These are converted to double-membrane vesicles (DMVs) containing viral ssRNA and then converted to other crimped membranes, which together form a reticulovesicular network. Nsp3, 4, and 6 of SARS-CoV contain transmembrane domains and are all responsible for the formation of DMVs [45]. In addition, the cis-acting element at the 5′ end of the nsp1 coding region facilitates the specific recognition of viral RNA, which is necessary for efficient virus replication [46].

MERS-CoV helicase (nsp13) is one of the most important viral replication enzymes and can profoundly affect tropism and virulence [47]. Nsp13 unfolds DNA and RNA in the 5′ to 3′ direction and is a kinematic protein that catalyzes the progressive separation of double-stranded nucleic acids into two single-stranded nucleic acids, using energy generated by ATP hydrolysis. Therefore, the nsp13 helicase can be used as a therapeutic target to inhibit the replication of MERS-CoV [48]. In addition, nsp8 has major activity in viral replication; nsp12 (RNA-dependent RNA polymerase (RdRp)) plays a role in virus replication and transcription and can be used as a diagnostic (RdRpSeq assay) and as an antiviral target (polymerase inhibitor); nsp14 has exonuclease activity; and nsp15 has endoribonuclease activity, and can effectively prevent the activation of dsRNA sensor (including melanoma differentiation-related protein 5 (Mda5), OAS, and PKR) in host cells [9,49,50].

4.3. Methyltransferase inhibition
Nsp16 is an S-adenosine-L-methionine (SAM)-dependent 2'-O-methyltransferase (2'-O-MTase), and nsp10 plays an important role in regulating 2'-O-MTase activity. SAM binding can promote the assembly of the nsp10/nsp16 complex, which enzymatically converts 7mGppG (cap-0) to 7mGpppG2’Om (cap-1) RNA in a SAM-dependent manner through 2’-O-methylation of SAM. Alanine mutagenesis has been used to identify the nsp16 residues that affect RNA recognition. The balance of SAM/S-adenosyl-L-homocysteine (SAH) can regulate 2'-O-methyltransferase activity, which increases SAH hydrolyase inhibition and can interfere with CoV replication cycles [51].

4.4. Membrane proliferation
Working together, nsp3 and nsp4 exert their effects in pairing membranes. Nsp6 can promote membrane proliferation by forming perinuclear vesicles, which is thought to require full-length nsp3, because no DMVs are seen in cells co-expressing C-terminally truncated nsp3 with nsp4 and nsp6 [52].

4.5. Interaction with the host
4.5.1. IFN antagonism
Most adaptive events occur through nsp3, which inhibits the IFN response via its deubiquitination and de-esterification activity [41]. Nsp3 is currently undergoing selection, based on MERS-CoV that has been isolated from humans and camels [44]. Positive selection changes in nsp3 (R911C) were observed in human-only viruses, suggesting that virus adaptation in humans represents a potential selective pressure [44]. Nsp16 helps the virus to escape from cellular innate immunity and uses IFN-induced protein with tetratricopeptide repeats 1 (IFIT-1) protein to inhibit viral translation [34]. Using reverse genetics, dsnp16-mutated MERS-CoV showed attenuation based on type 1 IFN; the mutation was partially recovered in the absence of IFIT-1 [53].

4.5.2. Deubiquitination
PLpro’s ubiquitin-like domain (Ubl) becomes fully flexible after binding to ubiquitin, and its increased flexibility is important for its interaction with other downstream proteins and for inhibition of innate immunity [54]. The four major residues involved in deubiquitination-L106, R168, P163, and F265 are conserved in all
There is no completely effective treatment for MERS-CoV. Current treatment methods mainly imitate the treatment of SARS-CoV, and comprise the following: symptomatic treatment, including biological therapy such as monoclonal antibodies (mAbs), blockers, protease inhibitors, corticosteroids, and IFN; chemical drugs, such as Acyclovir [61], chlorpromazine hydrochloride [62], loperamide, and lopinavir [63]; broad-spectrum antibiotics, such as ribavirin, lopinavir-ritonavir, or mycophenolate mofetil [64]; and nanoparticle vaccines [65]. However, well-organized clinical trials have not yet been carried out. Therefore, we analyzed potential prevention and treatment methods from the perspective of their molecular characteristics, which provides a reference for the development of effective and targeted prevention and treatment, and especially of biological strategies.

5. Potential strategies to treat MERS

There are no completely effective treatments for MERS-CoV. The mAbs are regarded as a potential intervention method and have been used to diagnose many diseases. The main products are antibodies toward S protein, interferons (IFNs), and broad-spectrum antibiotics. The mAbs are regarded as a potential intervention method and have been used to diagnose many diseases. The main products are antibodies toward S protein, interferons (IFNs), and broad-spectrum antibiotics.

4.5.3. Inhibition of the expression and translation of host mRNA

Nsp1 inhibits the host innate immune response by binding to dsRNA and cell double-stranded DNA; therefore, it is considered to be the best checkpoint of viral invasion [56]. At the same time, the C-terminus of nsp1 targets TNF receptor-associated factor 3 (TRAF-3) to inhibit the production of IFN-β [57]. In addition, activation of interferon-regulated transcription factor 3 (IRF3) [58] and PKR can be inhibited by other nsp1 domains [59]. Nsp1 of CoV may also interact with cyclophilin, and is considered to be a major virulence factor because it degrades host mRNA. The mRNA degradation activity of MERS-CoV nsp1 is separate from its translational inhibitory function. Furthermore, certain residues of MERS-CoV nsp1 are crucial for evading translational shutdown [46]. The escape of MERS-CoV mRNAs from inhibition by MERS-CoV nsp1 is promoted by their cytoplasmic origin [60].

5. Possible treatments for MERS-CoV, but differ from other betacoronaviruses. Thus, down-regulation of the deubiquitination of nsp3 may lead to a weakened interaction between MERS-CoV and the host immune system [54,55].

Table 2

| Therapeutic products | Targets | In vivo/in vitro | Safety/advantages |
|----------------------|---------|-----------------|------------------|
| Mersmab              | S1 RBD  | In vitro        | —                |
| m336, m337, m338     | S1 RBD  | In vitro        | —                |
| MERS-4, MERS-27      | S1 RBD  | In vitro        | —                |
| 4C2                  | S1 RBD  | In vitro        | —                |
| hM5-1                | S1 RBD  | In vitro        | —                |
| LCA60                | S1 RBD  | In vitro        | —                |
| 3B11-N               | S1 RBD  | In vitro        | —                |
| 2F9, 1F7, YS110      | Human-anti-DPP4 | In vitro | —                |
| 1E9, 1F8, 3A1        | S1 RBD  | In vitro        | —                |
| 3B12, 3C12, 3B11, M14D3 | S1 RBD  | In vitro        | —                |
| RBD s377-588-Fc IgG fusion | RBD-IgG fusion | In vitro/in vivo (mouse) | —                |
| G4                   | S1 RBD  | In vitro        | —                |
| Full-length S protein proprietary nanoparticles | S protein | In vitro/in vivo (mouse) | —                |
| MVA expressing full-length S protein | S protein | In vitro/in vivo (mouse, camel) | —                |
| Ad5 or ad41 adenovirus expressing full-length S protein | S protein | In vitro/in vivo (mouse) | —                |
| Measles virus expressing full-length S protein (vaccine candidate) | S protein | In vitro/in vivo (mouse) | —                |
| GLS-5300 plasmid vaccine | S protein | In vitro/in vivo (mouse, camels, and macaques); human clinical trials | —                |
| MERS-GD27 and MERS-GD33 | S protein | In vitro/in vivo | —                |
| HR2P                 | Anti-HR2 | In vitro        | —                |
| HR2P-M2              | Anti-HR2 | In vitro/in vivo (mouse) | —                |
| IFNs                 | IFN antagonists | In vivo/in vivo (mouse), SARS-CoV | —                |
| Camostat             | TMPRSS2 inhibitor | In vivo (mouse), SARS-CoV | —                |
| Nafamostat           | TMPRSS2 inhibitor | Split-protein-based cell–cell fusion assay | —                |
| Teicoplanin dalbavancin | Orivitavacin telavancin | Cathespin L inhibitor | High-throughput screening | —                |
| 6-mercaptopurine (6MP) | Ptpro inhibitor | In vitro | —                |
| 6-thioguanine (6TG)  | F2124-0890 | Ptpro inhibitor | In vitro | —                |
| Lopinavir            | Mpro | In vitro/in vivo (marmosets) | High activity in low micromolar range in vitro; better outcomes, reduced mortality in marmosets | —                |

5.1. Strategies related to the S protein

5.1.1. Antibodies toward S protein

The mAbs are regarded as a potential intervention method and have been used to diagnose many diseases. The main products are antibodies toward S protein, interferons (IFNs), and broad-spectrum antibiotics. The mAbs are regarded as a potential intervention method and have been used to diagnose many diseases. The main products are antibodies toward S protein, interferons (IFNs), and broad-spectrum antibiotics.
and show strong resistance to MERS-CoV-neutralizing activity. Table 2 describes other studies on potential antibodies and mAbs. Potential antibodies REGN3051 and REGN3048 have demonstrated effective prophylaxis in MERS-CoV-infected animal models [70,71], as have the following treatments: Mersmab [72]; IE9, IF8, 3A1, 2F9, 1F7, and YS110 [73]; hmS-1 [74]; 4C2 [75]; and RBD s377-588-Fc IgG fusion [76]. G4 recognizes the variable glycosylation loops in CoVs that define the four conformational states of the trimer. These studies may contribute to our understanding of fusion initiation and provide a basis for the design of structure-based CoV vaccines [5,77].

5.1.2. Inhibitors
MERS-CoV SP is essential for the virus to enter cells; therefore, other therapeutic agents that blockade viral cell membrane fusion should be exploited, such as feline protein inhibitors [78], TMPRSS2 inhibitors [79], PLpro inhibitors [41], furin inhibitors [80], kinase inhibitors [81], and IFN-induced transmembrane (IFITM) proteins [82].

5.1.3. Peptides
HR1P at position 998–1038 and HR2P at positions 1251–1286 have been identified by Lu et al. [19] and Liu et al. [83] as being responsible for the formation of the fusion core. The HR2P peptide can inhibit viral replication of MERS-CoV in cell lines, such as Calu-3 and HFL [19]. HR2P plays a role in the inhibition of the replication of MERS-CoV and its stimulatory fusion. Although there is little knowledge concerning assembly and release, inhibiting these viral processes may be an important goal in the future [64,84].

5.1.4. Potential therapeutic components
Low-temperature electron microscopy recently revealed a global pre-fusional structure of the full-length S-exodomain, indicating that the NTD and C terminal domain (CTD) form a “V” shape that helps the overall S trimer’s triangular appearance [85–87]. The S2 subunit is linked to the viral membrane and is characterized by the presence of a long alpha helix. This structural information could form the basis for the structure-based immunogen design of vaccines against betacoronaviruses. The combination of computational biology and virology could accelerate advanced designs of agents acting against MERS-CoV, resulting in higher efficacy [64].

5.2. Strategies related to the N protein
The N protein of MERS-CoV is abundantly produced during infection and shows strong immunogenicity, indicating that it is an ideal antigen for virus antibody detection. Anti-N IgG can be used as an indicator of susceptibility to human CoV infection [88]. Reports have described new methods to generate mAbs directed against N proteins. Using the wheat germ cell protein synthesis system, a large number of MERS-CoV N protein antigens were successfully prepared in a highly soluble and intact immune state [89].

5.3. Potential strategies to treat MERS-CoV based on its characteristics
Given the biological characteristics of MERS-CoV, infection prevention and control measures are critical to prevent the possible spread of this virus. For patients with MERS, effective early diagnosis and early treatment are difficult to achieve, mainly because of atypical early symptoms, the limitations of detection methods, and airborne transmission. Therefore, regardless of the diagnosis, healthcare providers should always take consistent standard precautions for all patients. IgM-type antibodies against MERS-CoV proteins need to be detected more effectively, necessitating the development of more effective antibodies.

6. Conclusion
Explosive epidemics of MERS-CoV pose a serious threat to global public health and emphasize the need to further investigate the epidemiology and pathogenesis of this virus, in addition to developing effective therapeutic and preventive drugs against MERS-CoV infection. Despite rapid advances in diagnostics and public health measures, new MERS-CoV cases are still being reported. This suggests that multiple interventions targeting different affected populations may be necessary to stop these outbreaks. As described herein, the structural information associated with the MERS-CoV proteins may be used to develop different potential interventions to limit the outbreak of MERS-CoV. There is a need to better understand the pathogenesis of MERS-CoV in order to identify viral and host factors that play an important role in the development of MERS in humans; this may provide potentially novel therapeutic and intervention options.

Acknowledgements
This work was supported by the National Science and Technology Major Project for the Control and Prevention of Major Infectious Diseases in China (2018ZX10711001 and 2018ZX10102001).

Compliance with ethics guidelines
Yan-Hua Li, Chen-Yu Hu, Nan-Ping Wu, Hang-Ping Yao, and Lan-Juan Li declare that they have no conflict of interest or financial conflicts to disclose.

References
[1] Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18(8):e217–27.
[2] Lee H, Lei H, Santarriero BD, Catué JL, Cao S, Rice AJ, et al. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem Biol 2015;10(6):1456–65.
[3] Choi J, Kim MG, Oh YK, Kim YB. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review. Expert Opin Ther Pat 2017;27(6):721–31.
[4] Zaki AM, Van Boeheimen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814–20.
[5] Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA 2017;114(35):E7348–57.
[6] Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomal cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 2018;18(4):410–8.
[7] Van Boeheimen S, De Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012;3(6):e00473–512.
[8] Frey KG, Redden CL, Bishop-Lilly KA, Johnson R, Hensley LE, Raviprakash K, et al. Full-genome sequence of human coronavirus 2c jordan-N3/2012 after serial passage in mammalian cells. Genome Announc 2014;2(3):e00324–414.
[9] Chan JF, Lau SK, To KK, Cheng VC, Wai PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015;28(2):465–522.
[10] Cotten M, Lam TT, Watson SJ, Palser AL, Petrova V, Grant P, et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronaviruses. Emerg Infect Dis 2013;19(5):736–42.
[11] Widagdo W, Okba NMA, Stalin Raj V, Haagmans BL. MERS-coronavirus: from discovery to intervention. One Health 2016;3:11–6.
[12] Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005;309(5742):1864–8.
[13] Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013;8(12):e81587.
[14] Lu G, Hu Y, Wang Q, Ji J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013;500 (7461):227–31.
[15] Ma C, Li Y, Wang L, Zhao G, Tao X, Teng CT, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 2014;32(18):2100–8.

[16] Mou H, Raj VS, Van Kuppevell FJ, Rottier PJ, Haagmans BL, Bosch BJ. The receptor-binding domain of the novel Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013;87(16):7937–83.

[17] Lan J, Yao Y, Deng Y, Hu Y, Bao L, Huang B, et al. The recombinant N-terminal domain of spike protein as a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 2017;35(3):10–8.

[18] Zumla A, Huis DE, Perlman S. Middle East respiratory syndrome. Lancet 2015;386(9975):995–1007.

[19] Lu L, Liu Q, Zhu H-W, Qin L, Liu L, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014;5:3067.

[20] Miller JK, Whittaker GR. Host cell proteins: critical determinants of coronavirus tropism and pathogenesis. Virus Res 2015;202:120–34.

[21] Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining “host jump” of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015;23(8):468–78.

[22] Surya W, Li Y, Verdià-Bàguena C, Aguilera VM, Torres J. MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels. Virus Res 2015;201:61–6.

[23] Westerbeek JW, Machamer CE. A coronavirus protein is present in two distinct pools: cell Deubiquitinase effects on assembly and the secretory pathway. J Virol 2015;89(18):9133–14.

[24] Xie Q, He X, Yang F, Liu X, Li Y, Liu Y, et al. Analysis of the genome sequence and prediction of B-cell epitopes of the envelope protein of Middle East respiratory syndrome coronavirus. IEEE/ACM Trans Comput Biol Bioinform 2018;15(4):1344–50.

[25] Liu J, Sun Y, QJ, Chi F, Hu W, Gao F, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 2010;202(8):1171–80.

[26] De Haan CA, Rottier PJ. Molecular interactions in the assembly of coronavirus. Adv Virus Res 2005;65:165–230.

[27] Lin SC, Ho CT, Chuang WH, L.S, Wang TT, Lin CC. Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis 2017;17(1):144.

[28] Szelaez B, Kabala W, Kusi K, Zdzalik M, Twarda-Clapa A, Golik P, et al. Structural characterization of human coronavirus NL63 N protein. J Virol 2017;91(11):e02503–16.

[29] Hu Y, Li W, Gao T, Cui Y, Jin Y, Li P, et al. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. J Virol 2017;91(8):e01243–16.

[30] Grunewald ME, Fehr AR, Atmer J, Perlman S. MERS-CoV nucleocapsid protein is ADP-ribosylated. Virology 2018;517:120–8.

[31] Papageorgiou D, Lichardus MC, Véron AA, Fernando F, Sévogol M, Canard B, et al. Structural characterization of the N-terminal part of the MERS-CoV nucleocapsid by X-ray diffraction and small-angle X-ray scattering. Acta Crystallogr D Struct Biol 2016;72(Pt 2 F):192–202.

[32] Banuls AL, Aragao LE, Monreal RL, De Cuéllar Takahashi M, Endo Y, et al. Deconstructing the lectin pathway in the pathogenesis of experimental inflammatory arthritis: essential role of the lectin ficolin B and mannos-binding protein-associated serine protease 2. J Immunol 2017;199(5):1835–45.

[33] Bolwig GM, Bruder JT, Hearing P. Different binding site requirements for coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015;23(8):468–78.

[34] Qian W, Wei X, Guo K, Li Y, Lin X, Zou Z, et al. The C-terminal effector domain of nonstructural protein 1 of MERS virus blocks IFN-β production by targeting TNF receptor-associated factor-3. Front Immunol 2017;8:779.

[35] Li Y, Li H, Li J, Li ZH, Chen GW, Chang CX, et al. Role of N terminus-truncated NS1 proteins of influenza A virus in inhibiting IRF3 activation. J Virol 2016;90(9):4696–705.

[36] Schierhorn KL, Jolmes F, Bespalowa J, Saenger S, Peteranderl C, Dzieciolowski J, et al. Middle East respiratory syndrome coronavirus nonstructural protein 1b inhibits host acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. Mbio 2013;4(4):e00524–613.

[37] Menachery VD, Gralinski LE, Mitchell HD, Dinmon HK 3rd, Leist SR, Yount BL Jr, et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNA-dependent protein kinase. J Virol 2015;90(5):e00197–315.

[38] Menachery VD, Alhagag MM, Wong L, Tidball MJ, Seale GR. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. Mbio 2013;4(4):e00524–613.

[39] Virology 2013;94(Pt 8):1749–60

[40] Akkaya KM, Kus K, Zdzalik M, Twarda-Clapa A, Golik P, et al. Structural characterization of human coronavirus NL63 N protein. J Virol 2017;91(11):e02503–16.

[41] J Virol 2017;91(8):e01243–16.

[42] Bolwog GM, Bruder JT, Hearing P. Different binding site requirements for coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015;23(8):468–78.

[43] Menachery VD, Gralinski LE, Mitchell HD, Dinmon HK 3rd, Leist SR, Yount BL Jr, et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNA-dependent protein kinase. J Virol 2015;90(5):e00197–315.

[44] Virology 2013;94(Pt 8):1749–60

[45] Akkaya KM, Kus K, Zdzalik M, Twarda-Clapa A, Golik P, et al. Structural characterization of human coronavirus NL63 N protein. J Virol 2017;91(11):e02503–16.

[46] J Virol 2017;91(8):e01243–16.

[47] Bolwog GM, Bruder JT, Hearing P. Different binding site requirements for coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015;23(8):468–78.

[48] Menachery VD, Gralinski LE, Mitchell HD, Dinmon HK 3rd, Leist SR, Yount BL Jr, et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNA-dependent protein kinase. J Virol 2015;90(5):e00197–315.

[49] Virology 2013;94(Pt 8):1749–60

[50] Akkaya KM, Kus K, Zdzalik M, Twarda-Clapa A, Golik P, et al. Structural characterization of human coronavirus NL63 N protein. J Virol 2017;91(11):e02503–16.

[51] J Virol 2017;91(8):e01243–16.

[52] Bolwog GM, Bruder JT, Hearing P. Different binding site requirements for coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015;23(8):468–78.

[53] Menachery VD, Gralinski LE, Mitchell HD, Dinmon HK 3rd, Leist SR, Yount BL Jr, et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNA-dependent protein kinase. J Virol 2015;90(5):e00197–315.
[68] Jiang L, Wang N, Zhuo T, Shi X, Poon KM, Wu Y, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014;6(234):234ra59.

[69] Niu P, Zhang S, Zhou P, Huang B, Deng Y, Qin K, et al. Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient. J Infect Dis 2018;218(8):1249–60.

[70] Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA 2015;112(28):8738–43.

[71] De Wit E, Feldmann F, Okumura A, Horne E, Dadd E, Saturday G, et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. J Virol 2014;88(12):7045–53.

[72] Rabaan AA, Alahmed SH, Bazzi AM, Alhani HM. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol 2017;66(9):1261–74.

[73] Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, et al. A humanized neutralizing antibody targeting the receptor-binding domain of the SARS-CoV-2 spike protein. Cell Res 2015;25(11):1237–49.

[74] Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015;6:7712.

[75] Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, et al. Pre-fusion structure of a human coronavirus spike protein. Structure 2016;24(10):1184–95.

[76] Walls AC, Tortorici MA, Frenz B, Snijder J, Li W, Rey FA, et al. Cryo-electron microscopy. Methods Mol Biol 2016;1282:1–23.

[77] Walls AC, Frenz B, Snijder J, Li W, Rey FA, et al. Cryo-electron microscopy. Methods Mol Biol 2016;1282:1–23.

[78] Walls AC, Tortorici MA, Bosch BJ, Frenz B, Rottier PJ, DiMaio F, et al. Crucial steps in the structure determination of a coronavirus spike glycoprotein using cryo-electron microscopy. Structure 2016;24(10):1184–95.

[79] Gao X, Zhou H, Wu C, Xiao Y, Ren L, Falan A-Baccalà G, et al. Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection. J Infect 2015;71(5):599–602.

[80] Yamaoka K, Matsuyama S, Fukushima S, Matsuura S, Matsushita Y, Kuroyama H, et al. Development of monoclonal antibody and diagnostic test for Middle East respiratory syndrome coronavirus using cell-free synthesized nucleocapsid antigen. Front Microbiol 2016;7:50.